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Triple-negative breast cancer is a heterogeneous
disease characterized by poor clinical outcomes
and a shortage of targeted treatment options. To
discover molecular features of triple-negative breast
cancer, we performed quantitative proteomics anal-
ysis of twenty human-derived breast cell lines and
four primary breast tumors to a depth of more than
12,000 distinct proteins. We used this data to identify
breast cancer subtypes at the protein level and
demonstrate the precise quantification of biomar-
kers, signaling proteins, and biological pathways by
mass spectrometry. We integrated proteomics data
with exome sequence resources to identify genomic
aberrations that affect protein expression. We per-
formed a high-throughput drug screen to identify
protein markers of drug sensitivity and understand
the mechanisms of drug resistance. The genome
and proteome provide complementary information
that, when combined, yield a powerful engine for
therapeutic discovery. This resource is available to
the cancer research community to catalyze further
analysis and investigation.
INTRODUCTION
A key challenge for medicine in the 21st century is to harness
the predictive power of molecular data to eradicate cancer
(Arteaga and Baselga, 2012; Vidal et al., 2012; Weinstein
et al., 1997). Like other cancers, breast cancer is caused
by a series of inherited and/or acquired genetic aberrations
that eventually lead to uncontrolled cell proliferation and
metastasis. The diverse genetic drivers of breast cancer
have been characterized in exquisite detail (Banerji et al.,
2012; Curtis et al., 2012; Perou et al., 2000; Prat and Perou,
2011; Cancer Genome Atlas Network, 2012; Vogelstein et al.,
2013). However, characterization of the proteome has lagged
behind.630 Cell Reports 11, 630–644, April 28, 2015 ª2015 The AuthorsAt the functional level, relevant genomic aberrations affect
cellular functions by altering the activity and abundance of pro-
teins. These effects are context specific and very much depend
on the unique catalog of proteins expressed by different cell
types. For example, a mutation in the BRAF kinase might have
different functional outcomes in skin cancer than in liver or breast
cancer. In addition to driving cellular functions, proteins are the
most actionable and drug-treatable cellular components. There-
fore, protein measurements are important to understand breast
cancer and delineate breast cancer therapies.
In fact, protein measurements are being used today to classify
breast cancer types according to their receptor status, in which
the presence or absence of three cellular receptors (estrogen re-
ceptor ESR1, progesterone receptor PGR, and human epidermal
growth factor receptor-2 ERBB2) is assessed via immunohisto-
chemistry. Despite the reduced number of molecular features
measured, this classification is the most useful today for chemo-
therapy selection. Irrespective of genomic aberrations, more
than 80% of breast cancers express one or more of these recep-
tors (Howlader et al., 2014) and are treatable by hormone depri-
vation and/or ERBB2 inhibition (Untch et al., 2014). Targeted
therapies are not currently available for tumors that do not ex-
press these receptors, which are collectively referred to as tri-
ple-negative breast cancer (TNBC). TNBC is an important and
unmet clinical problem. It tends to be more aggressive, is corre-
lated with worse prognosis than receptor-positive subtypes (Hu-
dis and Gianni, 2011), and is more common among young and
African American women (Howlader et al., 2014). Identifying sub-
types within the TNBC type, and proteins within those subtypes
that can serve as therapeutic targets, will be extremely valuable.
Among protein measurements, reverse-phase protein arrays
(RPPA) have been one of the most widely adopted tools for
integrated genomics and drug sensitivity analysis, but a key lim-
itation of RPPA technology is its lack of proteome coverage,
generally less than 200 analytes (Tibes et al., 2006). As such,
mRNA expression has been used as a proxy for protein levels,
despite mediocre quantitative concordance (Gygi et al., 1999;
Maier et al., 2009). Both mRNA and protein expression using
RPPA outperform genomic data as predictors of drug sensitivity
and clinical outcomes (Costello et al., 2014; Yuan et al., 2014).
These results highlight the potential of systematic protein
expression analyses for breast cancer research in general and
drug discovery in particular.
It is an excellent time to further investigate the TNBCproteome
using more comprehensive techniques. Mass spectrometry in
the form of ‘‘shotgun proteomics’’ is highly quantitative, and
has reached the speed and sensitivity to measure proteomes
at a depth comparable to gene expression studies (Kim et al.,
2014; Wilhelm et al., 2014). In fact, proteomics is already making
an impact in breast cancer research (Geiger et al., 2012a; Mog-
haddas Gholami et al., 2013; Kennedy et al., 2014), but yet, to
show its full potential, proteomics needs to be integrated with
other types of big data.
Here we present an integrative approach using quantitative
mass spectrometry to characterize TNBC proteomes both as
readouts of genetic abnormality and as predictors of drug sensi-
tivity. The goals of this work were to refine our understanding of
breast cancer biology as an integrated proteogenomic land-
scape and to identify molecular diagnostic markers to improve
drug selection in TNBC.
RESULTS
The TNBC Proteome
We assembled a panel of 20 human breast cell lines and four
clinical tumors to analyze the proteomic landscape of TNBC (Fig-
ure 1A). These included 16 triple-negative cell lines covering
mesenchymal-, luminal-, and basal-like subtypes, as well as
three receptor-positive and one non-tumorigenic cell line to
serve as a basis for comparison (Lehmann et al., 2011; Neve
et al., 2006). Primary tumor tissues were derived from patients
with metastatic TNBC (stages II to III). Cell lines were cultured
and analyzed in duplicate to assess the precision of protein
quantification. Proteins were digested in parallel with either
lysyl-endopeptidase (LysC) or trypsin and separated at the
peptide level into five fractions to enhance proteome coverage
(Figure 1B). We used liquid chromatography-tandem mass
spectrometry (LC-MS/MS) on a hybrid quadrupole-orbitrap
mass spectrometer to acquire quantitative profiles of the pep-
tides present in each fraction.
In total, more than 450 peptide fractions were analyzed,
yielding approximately 20 million high-resolution mass spectra.
Across the entire dataset, we identified 289,819 non-redundant
peptide sequences mapping to at least 12,775 distinct proteins
encoded by 11,466 genes (protein false discovery rate [FDR] <
1%). To facilitate comparison of specific protein isoforms, we
additionally retained in our data truncated protein isoforms hav-
ing high sequence coverage, bringing the total proteins analyzed
to 15,524. The median protein had 15 peptide matches, four iso-
form-specific peptide matches, and shared peptides with only
one other protein in the dataset (Figures S1A–S1C). Median pro-
tein sequence coverage was 52%.
The number of proteins identified was consistent across cell
lines, tissues, and replicates. On average, 80% of proteins
were identified in both replicates. At least 9,000 proteins were
found in each cell line (Figure 1C), which agrees well with other
recent deep proteome experiments (Beck et al., 2011; Geiger
et al., 2012b; Moghaddas Gholami et al., 2013; Nagaraj et al.,
2011). These proteins represent 56% of the 20,537 genes anno-tated in Uniprot/Swiss-Prot and at least 75% of genes included
in the catalog of somatic mutations in cancer (COSMIC) (Fig-
ure 1D). As expected, we achieved near complete coverage of
gene ontology categories involved in core cellular functions,
such as primarymetabolism, protein synthesis, and general tran-
scription, and lower coverage of tissue-specific categories, such
as transcription factors and receptors (Figure 1E).
To infer protein absolute abundances (as copies/cell), we
used intensity-based absolute quantitation (iBAQ). Quantitative
reproducibility between biological replicates was uniformly
high across all cell lines, with an average R2 equal to 0.92 (Fig-
ure 1F; Figure S1D). Proteins that were highly abundant and
identified in all samples were the most reproducibly quantified
(median CV = 16%, Figure S1E). By comparison, the average
R2 between different cell lines was 0.72, indicating significant dif-
ferences in global protein expression.
The data presented here comprises more than 200,000 quan-
titative measurements of absolute protein abundance (Table S1).
Innovations in instrumentation and extensive peptide fraction-
ation prior to analysis have greatly increased the sensitivity and
reproducibility of shotgun proteomics analysis, and our quantita-
tive results compared favorably with a recent targeted prote-
omics study on many of the same cell lines (Kennedy et al.,
2014) completed by the Clinical Proteomic Tumor Analysis
Consortium (CPTAC). To facilitate use and dissemination of the
data, we have developed a web resource (https://zucchini.gs.
washington.edu/BreastCancerProteome/) in which protein
abundances can be queried and correlated to genomic and
drug sensitivity data, as presented below. To demonstrate the
validity of our dataset as a quantitative resource, we examined
several clinical breast cancer biomarkers including ESR1,
PGR, and ERBB2 (Figure 2). These measurements accurately
reproduce the known classification of cell lines based on immu-
nocytochemistry (Subik et al., 2010) and correspond with known
copy-number (CN) amplifications. In contrast to antibody stain-
ing, which assesses the presence or absence of expression,
mass spectrometry provides sensitive and precise quantitation
over a broad range. This is an important consideration for
markers such as Ki-67, which are dynamically expressed in all
cells. As another example, the cell line MDA-MB-453 stains
negative for ERBB2 (Vranic et al., 2011) and was classified as
a TNBC cell line (Neve et al., 2006), despite bearing a CN ampli-
fication. However, our results show that MDA-MB-453 ex-
pressed ERBB2 at levels 20-fold higher than the median,
compared to several-hundred-fold overexpression of ERBB2
by cell lines such as BT474 and SKBR3.
Quantitative Analysis of TNBC Proteomic Subtypes
Molecular subtyping using gene expression or copy-number ab-
erration has been used extensively to characterize clinical breast
cancer specimens and cell lines (Banerji et al., 2012; Lehmann
et al., 2011; Prat and Perou, 2011). We used hierarchical clus-
tering to identify patterns based on correlation of protein expres-
sion profiles. This approach classified the panel of cell lines into
two overarching groups containing four clusters (Figure 3A). To
illustrate the relationship between driver gene alterations and
proteome profiles, we show the most frequent census mutations
and copy-number aberrations for each cell line (Figure 3A, top).Cell Reports 11, 630–644, April 28, 2015 ª2015 The Authors 631
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Figure 1. Mass Spectrometry-Based Profiling of TNBC
(A) Overview of samples analyzed is shown. N, normal epithelial; +, ER/PR/ERBB2+; L, luminal-like; M, mesenchymal-like; B, basal-like; ?, not matched. TNBC
cell line classifications are according to Lehmann et al. (2011).
(B) Workflow of proteomics sample preparation and data collection is shown.
(C) Average number of proteins identified in each replicate (blue bars) and total number of proteins for each cell line (green bars) are shown. Error bars
represent SD.
(D) Percentages of identified proteins relative to the Uniprot/Swiss-Prot database (left) and the COSMIC census (right) are shown.
(E) Number and percentage representations of indicated gene ontology categories are shown.
(F) Representative scatter plot for cell line SKBR3 replicate protein measurements shows quantitative reproducibility of iBAQ protein abundance.Cell lines with similar genetic abnormalities tended to cluster
together. As has been observed previously (Cancer Genome
Atlas Network, 2012), PIK3CA mutations were associated
with luminal breast cancer subtypes (80% of the cell lines in
cluster 1), whereas TP53 mutations were characteristic of
TNBC (100% of the cell lines in clusters 3 and 4). Mutations in
the tumor suppressor NF1 were exclusive to the mesen-
chymal-like subtype (cluster 4) and BCR mutations were exclu-
sive to luminal cells (cluster 1).632 Cell Reports 11, 630–644, April 28, 2015 ª2015 The AuthorsProtein expression patterns within subtype clusters were
still highly cell-type specific. To better illustrate this, we used
principal component analysis (PCA) to project the distances
between each proteome onto a two-dimensional coordinate
system. Some of the sample proteomes formed tight clusters,
while others were more distantly related to those in the same
group (Figure 3B). Additional principal component dimensions
are necessary to capture the proximity of cell lines, such as
MFM223, BT474, and HCC1599, to their respective subtypes.
Figure 2. Quantification of Clinical Breast Cancer Biomarkers
ESR1, estrogen receptor; PGR, progesterone receptor; ERBB2, human
epidermal growth factor receptor-2; TP53, tumor protein p53; MKI67, Ki-67
antigen; EGFR, human epidermal growth factor receptor. Sample labels are
shown (bottom). Absolute protein abundancewas calculated using iBAQ. Error
bars represent SD. Red dots indicate gene CN amplification (more than seven
copies).Intra-subtype correlation was also modest in earlier classifica-
tion studies using mRNA expression (Lehmann et al., 2011),
and the differences in mRNAmay be further amplified at the pro-
tein level. The heterogeneity of protein expression underscores
the importance of data-driven cell line selection in cancer
research.
Accurate analysis of genes, transcripts, or proteins from het-
erogeneous clinical specimens represents a major challenge
for precision medicine. The proteins expressed >10-fold in tu-
mors versus the cell lines were enriched with proteins from blood
cells and plasma (p < 0.001). These proteins accounted for as
much as 20% of the total proteome intensity from the tumors.
Given that TNBC cell lines should better represent the cellular
component of the tumor, we correlated tumor samples to the
centroids from each cell line cluster to identify to which proteo-
mic subtype they belonged; we found that they were all more
similar to clusters 3 and 4, an observation that also can be
made based on PCA (Figure 3B).Nevertheless, many proteins significantly over- or underex-
pressed within each cluster could be identified. We were partic-
ularly interested in potential drug targets and proteins known to
be involved in cancer biology. For example, the protein STAT5A,
a pro-survival transcription factor, was expressed at high levels
in the tumors and mesenchymal-like cell lines (Figure 3C). Using
the first cluster as an example, we show how these proteins
can be identified using our web-based resource (Figure S2A).
The transcription factor FOXA1 was exclusively expressed by
luminal-like cells, whereas TGFB1 was not found (Figure S2B).
PPM1A, a protein involved in the suppression of TGF-b-signaling
pathways (Lin et al., 2006), was decreased in TNBC, while many
proteins involved in immunity and metastasis, such as POSTN,
MYLK, andHLA-A, were expressed at higher levels in TNBC (Fig-
ure S3A). Some of these proteins are thought to be provided by
tumor-infiltrating immune cells and fibroblasts (Quail and Joyce,
2013), but here we show they also are abundant in the homoge-
nous conditions of cell culture.
The composition of each cluster showed striking similarity to
subtypes defined by mRNA expression arrays and morpholog-
ical studies (Kenny et al., 2007; Lehmann et al., 2011; Neve
et al., 2006). Cluster 1 contained the luminal breast cancer cell
lines SKBR3, MCF7, and BT474 as well as luminal-androgen-re-
ceptor cell line MFM-223, which expresses the androgen recep-
tor protein, and MDA-MB-453, which overexpresses ERBB2 as
described above. The set of proteins that was highly expressed
by these cell lines was enriched for functions typically expected
of cancer cells, including insulin and ErbB signaling, glycolysis,
and nucleotide excision repair (Figure 3D). Cluster 2,most similar
to the basal-like 2 gene expression subtype, contained, DU4475,
SW527, HCC1806, MDA-MB-436, and the normal breast epithe-
lial cell line MCF10A. Cluster 3 included all basal-like 1 cell lines:
HCC38, HCC1143, HCC1937, BT20, and MDA-MB-468. Cluster
4, containing BT549, HS578T, MDA-MB-231, and MDA-MB-
157, was identical to ‘‘mesenchymal-like/claudin-low’’ subtype
(Lehmann et al., 2011), all showing stellate morphology in
three-dimensional culture (Kenny et al., 2007) and high invasive-
ness in chamber assays (Neve et al., 2006). To better understand
the biology of each subtype, we compared the distribution of
protein abundance within gene ontology categories. Interest-
ingly, luminal-like cells expressed higher levels of pathways
associated with proliferation, such as cell cycle, growth factor
signaling, metabolism, and DNA damage repair mechanisms
(Figure 3E; Figure S3B). TNBC cell types, particularly the tumors
and more invasive cells, expressed higher levels of pathways
associated with metastasis, such as ECM-receptor interaction,
cell adhesion, and angiogenesis (Figure 3E; Figure S3B). The ex-
pressions of proliferation and metastasis pathways were mutu-
ally exclusive, an observation also made in an analysis of
mRNA expression profiles from claudin-low tumors (Prat et al.,
2010). Thus, therapies targeting immune and metastatic sig-
naling are an exciting avenue for TNBC treatment.
Differential Expression of Cancer-Signaling Proteins
The cancer genome has been studied extensively (Futreal et al.,
2004; Vogelstein et al., 2013). We sought to characterize the
abundance of proteins derived from known cancer census genes
and signaling pathways (Figure 4; Figure S4). The abundance ofCell Reports 11, 630–644, April 28, 2015 ª2015 The Authors 633
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Figure 3. The TNBC Proteome
(A) Hierarchical clustering of protein expression profiles computed using centered Pearson’s correlation identified four proteome subtypes as indicated. Protein
expression values were normalized to a scale from 0 to 1 prior to clustering. Frequent genetic aberrations are overlaid onto the proteome clustering results. Green
circles represent exonicmutations. Red and blue circles represent CNgain (more than seven copies) or loss (0 copies), respectively. Colored background shading
corresponds to cluster membership. At the time of writing, exome sequence and CN data were not available for MCF10A and SW527.
(B) Scatterplot of principal components 1 and 2. PCA was performed using protein expression profiles. Each point represents a sample. Colors represent hi-
erarchical cluster membership from (A).
(C) Biological pathways enriched from the indicated proteins clusters. Inverted log10 p values are shown.
(D) Representative example shows a protein upregulated in cluster 4 and tumors. STAT5A, signal transducer and activator of transcription 5A. Error bars
represent SD.
(E) Distribution of protein abundances within each cluster (colors) for indicated biological processes. For (A–E), cluster membership is indicated by the same
colors used in (A), with tumor samples indicated in yellow.
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Figure 4. Expression of Cancer-Signaling Proteins
(A–G) Distribution of absolute abundance for each protein in the signaling network. Chart titles indicate subnetwork membership. Each data point represents a
sample, color coded according to cluster membership from Figure 4A.
(H and I) Top 25 most differentially expressed proteins (highest SD between different samples) from (H) the COSMIC gene census or (I) the protein kinase su-
perfamily are shown.most signaling proteins spanned two to three orders of magni-
tude, but others were expressed similarly across all cell lines
(Figures 4A–4G). These proteins included several members of
the RAS-MAPK pathway, such as GRB2, HRAS/KRAS/NRAS,
MEK1/2, and ERK1/2. In certain cases, expression of these
proteins was associated with proteomic-based breast cancer
subtypes. For example, CHEK2, HMGA2, POT1, and IL6ST
were highly expressed by members of clusters 1 through 4,
respectively (Figures 4H and 4I). However, protein expression
was generally variable and cell-type specific. MLL3 was specif-
ically expressed by BT474, BT20, and tumor A, which were each
from different clusters (Figure 4H). HCC1806 and MDA-MB-436
specifically lacked expression of the protein kinase AKT1/2 (Fig-
ure 4B). PKCa was expressed at high levels in each of the cell
lines from cluster 4, but also was highly expressed in DU4475(Figure S4J). These results show that, despite overall concor-
dance of whole proteome profiles with various cellular pheno-
types, in most cases the expression of particular cancer proteins
did not uniformly belong to one subtype or another.
The identification of proteins with very specific outliers or large
dynamic range provides a valuable resource for TNBC drug
development efforts. EGFR, ERBB2, ESR1, and PGR exemplify
these properties (Figures 4A and S4D) and are already routine
clinical targets in breast cancer, but there are many others. For
example, ephrin type A receptors, which are involved in embry-
onic development and not normally present in adult tissues, were
overexpressed by several orders of magnitude in many TNBC
cell lines compared to luminal-like cells (Figure 4A). With the
increasing availability of comprehensive quantitative proteomics
datasets, protein expression should continue to be one of theCell Reports 11, 630–644, April 28, 2015 ª2015 The Authors 635
most valuable parameters for drug development and clinical
diagnostics.
Isoform-Specific Protein Expression
The identification and quantification of protein isoforms resulting
from alternative splicing is a significant challenge in proteomics,
arising from the reduced number of isoform-specific peptides
that are amenable to analysis bymass spectrometry. For this da-
taset, we first relied on isoform-specific peptides to unambigu-
ously identify proteins mapping to the same gene in the Uniprot
sequence database. This led to the identification of 1,860 protein
isoforms that corresponded to 844 genes, 52 of which were
members of theCOSMIC census. Next, we examined the relative
quantification of protein isoforms. Protein isoforms share long
segments of identical sequence but are missing certain protein
domains, resulting in altered signal intensity from those parts
of the protein.
We relied on manual inspection to analyze the expression of
isoforms for proteins involved in cancer progression. For most
proteins, different isoformswere nearly perfectly correlated, indi-
cating no difference in expression of specific isoforms, but there
were notable exceptions. For example, we identified variants in
the p65 subunit of the transcription factor NF-kB, the tumor an-
tigen CD47, and focal adhesion kinase PTK2. The protein
sequence of the NF-kB p65 variant is identical to the canonical
sequence until proline 344, followed by the read-through trans-
lation of 33 amino acids and an early stop (Figure 5A). The alter-
native sequence lacks many important regulatory regions
including the residues phosphorylated by IKKB that directly
affect its transcriptional activity (Sakurai et al., 1999). The p65
variant was detected in two cell lines and was expressed at
higher levels in all four tumor samples (Figure 5B). This result
was confirmed by an isoform-specific peptide, FSSVQLR, which
matched no other entry in the Uniprot protein sequence data-
base (Figure 5A). This finding was especially interesting since
the tumor proteomes were enriched in immuno-modulatory
pathways. NF-kB modulates the inflammatory response and
plays an important role in cancer by promoting metastasis
(Huber et al., 2004; Luo et al., 2004).
CD47 is an atypical G protein-coupled receptor with fivemem-
brane-spanning domains that participates in integrin signaling
and is proposed to have many important roles in cancer (Sick
et al., 2012).We detected two of the four known alternative splice
variants that differentially encode the cytoplasmic tail. The cell
line DU4475 expressed higher levels of the long isoform (Figures
5C and 5D), which is highly expressed in neurons (Brown and
Frazier, 2001). Although little is known about the functional differ-
ences between the isoforms, it is likely that this tail mediates
intracellular signaling downstream of the receptor.
PTK2, or focal adhesion kinase 1, is a tyrosine protein kinase
involved in cell migration (McLean et al., 2005). We confirmed
the presence of an N-terminally truncated form of this protein,
which lacks the FERM (4.1-Ezrin-Radixin-Moesin) domain (Fig-
ure 5E). The FERMdomain regulates PTK2 localization and inter-
action with other proteins to affect its activity (Frame et al., 2010).
Interestingly, the full-length form appeared to be expressed
higher in HS578T and BT20 cells based on the relative intensity
of N-terminal versus C-terminal peptides (Figures 5E and 5F).636 Cell Reports 11, 630–644, April 28, 2015 ª2015 The AuthorsThe differential expression of structural protein variants, many
of which occur post-translationally, could be a significant regula-
tory mechanism in cancer. Further work will be necessary to sys-
tematically identify and accurately quantify these events.
Proteogenomic Analysis Identifies Signatures of Driver
Mutations
Genetic aberrations such as sequence mutations and amplifica-
tions, which typically occur in regulatory proteins, can have
pleiotropic downstream effects on other proteins that more
directly drive cancer phenotypes. We integrated publicly avail-
able exome sequence and gene CN data from COSMIC (Forbes
et al., 2011) with proteome profiles from 18 cell lines. Protein
abundance trended positively with gene CN. The average
expression of all proteins in each CN bin correlated strongly
with CN (R = 0.96). However, it was more variable and correlated
poorly on a pairwise basis (n = 56,579, R = 0.19) (Figure 6A). For
example, the cancer census gene NDRG1 was not correlated
with CN (R = 0.06) and was not highly expressed even when
amplified (Figure 6B). This poor correlation is expected for pro-
teins under high transcriptional, translational, or proteasomal
control.
Driver mutations occur frequently in regulatory proteins such
as protein kinases, E3 ubiquitin ligases, and transcription fac-
tors, which alter the physiology of the cell by modulating the
abundance or activity of other proteins. For example, our data
showed that DU4475, the cell line with an APC mutation, ex-
pressed more than 4-fold median levels of b-catenin (p = 3.3 3
104, heteroscedastic t test) (Table S1), which APC normally tar-
gets for degradation. Initially we characterized cellular subtypes
according to protein abundance profiles and asked whether
frequent genetic mutations were associated with these subtypes
(Figure 3). An alternative analysis approach is to group cell lines
by their mutational status and ask whether the abundance of
specific proteins are associated with these mutations, as in the
b-catenin and APC example.
We reasoned that mutations in certain driver genes, such as
those in the same signaling pathway, would likely converge to
regulate common effectors. To determine the global effects of
driver gene mutations on protein expression, we systematically
evaluated gene-protein associations for frequently mutated
census genes (n R 3 cell lines) by comparing the abundance
of each protein in cell lines with versus without a mutation, and
plotted this information as a network. Driver genes and their
protein targets formed clusters according to their shared associ-
ations (Figure 6C). The number of significant (p < 0.001) associ-
ations for each gene ranged from 11 to 320 (Figure 6D). The
network degree distribution fit an exponential function (R2 =
0.99), revealing 233 hub proteins, each associated with three
or more cancer census genes (Figure 6E). Cell cycle was the
only significantly enriched gene ontology term among hub pro-
teins (p = 5.66 3 104). While not surprising, it demonstrates
that dysregulation of cell-cycle protein abundance may be a
common effect of diverse genetic mutations.
On an individual basis, proteins regulated downstream of ge-
netic lesions (e.g., TP53 loss of function) might represent more
suitable therapeutic targets than the gene product itself. Several
highly significant (p < 0.001) gene-protein associations are
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Figure 5. Differential Expression of Protein Isoforms
(A) Schematic of RELA (NF-kB subunit p65) mRNA sequence variants and intensity-based quantification of the isoform-specific peptide FSSVQLR in each
sample. Peptide intensity was divided by the total proteome intensity for normalization. The location of an exon read-through event is indicated.
(B) Scatterplot shows the full-length NF-kB protein versus the read-through variant, highlighting off-diagonal samples.
(C) Four alternative splice variants encode the cytoplasmic tail of integrin-associated protein CD47. The sequence of these variants is shown along with the
quantification of the peptide specific to isoform 1, AVEEPLNAFK.
(D) Scatterplot shows CD47 isoform 1 versus isoform 3, highlighting off-diagonal samples.
(E) Schematic shows N-terminally truncated form of focal adhesion kinase PTK2 and quantification of N-terminal/C-terminal intensity in each sample.
(F) Scatterplot shows PTK2 long form versus short form, highlighting off-diagonal samples.
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Figure 6. Proteogenomic Associations
(A) Boxplot shows the relationship of protein abundance to gene CN. Protein abundances were row-normalized to a scale of 0 to 1 to account for differences in
absolute expression.
(B) NDRG1 (N-myc downstream regulated gene 1) is a representative protein that was not correlated with CN. CN > 6 highlighted in red. R represents Pearson’s
correlation. Error bars represent SD between replicate measurements.
(C) Network of gene-protein associations. Each edge represents an association (p < 0.001) between a mutated census gene (gray nodes) and protein expression
(yellow nodes). Only genes from the COSMIC census mutated in at least three cell lines were analyzed. Node size represents the number of connections. The
network was plotted in Cytoscape using edge-weighted spring-embedded layout so that genes with common associations cluster together.
(D) Number of outgoing associations for each mutated gene in network is shown.
(E) Number of incoming associations for each target protein in network (node degree distribution). Cell-cycle proteins were enriched among proteins with three or
more associated genes (p = 5.66 3 104).
(F–J) Representative gene-protein associations (p < 0.001) for common genetic lesions in breast cancer. Protein is indicated in chart title, and mutated gene is
shown in italics below plot. Error bars represent SEM.
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shown (Figures 6F–6J). In the case of TP53, nearly all of the
significantly associated proteins were involved in DNA meta-
bolism and repair. One such protein was ecto-50-nucleotidase
(NT5E or CD73), a GPI-anchored cell surface enzyme involved
in the production of membrane-permeable nucleosides, which
can be used for nucleotide salvage (Zimmermann, 1992). Target-
ing it by small interfering RNA (siRNA) or small molecule inhibition
(using adenosine [(a,b)-methylene] diphosphate) arrested the
cell cycle and triggered apoptosis in MDA-MB-231 breast can-
cer cells (Zhi et al., 2010). Monoclonal antibodies against NT5E
also were demonstrated to block breast cancer metastasis
in vivo (Stagg et al., 2010). NT5E may be an effective drug target
specifically for cancers with TP53 mutations. In addition to the
discovery of potential drug targets, these proteins also could
be used as markers to infer whether or not a mutation is
deleterious.
Proteomics of Drug Sensitivity
To generate a resource for drug sensitivity prediction, we
screened the 16 TNBC cell lines from our panel against a library
of 160 compounds at eight different concentrations spanning
four orders of magnitude. We used this data to determine the
IC50, defined as the dose required to reach a 50% reduction in
cell viability, for each drug in each cell line (Table S2). Approxi-
mately three quarters (123/160) of the compounds elicited a
measurable response in at least one cell line, and each cell line
was sensitive to at least five compounds at sub-micromolar
doses. The distribution of responses for each drug was diverse
(Figure 7A). The IC50 distribution for most drugs spanned a
wide range, 790-fold on average. Some drugs were very specific
with few sensitive cell lines (e.g., everolimus, methotrexate, and
lapatinib), while other drugs were indiscriminate with few resis-
tant cell lines (e.g., bortezomib, paclitaxel, and MG132).
Next, we combined our pharmacological dataset with publicly
accessible data from the Genomics of Drug Sensitivity in Cancer
(CRx) resource (Yang et al., 2013) and performed regression
analysis against mass spectrometry-derived protein abun-
dances to discover proteomic markers of drug sensitivity or
resistance. We used hierarchical clustering to analyze global
patterns among drug sensitivity-protein expression relation-
ships, revealing many distinct clusters (Figure 7B). Drugs target-
ing proteins in the same pathway (e.g., BRAF andMEK inhibitors)
showed similar correlation profiles. Interestingly, proteins that
were part of the same pathways or complexes also clustered
together, which did not occur using protein expression data
alone (Figure 3A). The cluster that was highly enriched with mito-
chondrial proteins was associated with sensitivity to drugs that
might depend on mitochondrial protein expression (belinostat,
vorinostat, and obatoclax). For example, since protein acetyla-
tion is known to be enrichedwithin themitochondrial space, cells
with more mitochondria might be more sensitive to deacetylase
inhibition. In a similar vein, the cluster that was enriched with
translation factors was associated with increased sensitivity to
proteasome inhibitors MG132 and bortezomib. These results
show that the integration of proteomics and drug sensitivity
data using regression analysis provides a rich resource to iden-
tify unexpected modes of action and to discover new features of
target pathways.We used the regression analysis to select the most effective
and robust drugs for known targets. For example, EGFR expres-
sion was, as expected, strongly associated with sensitivity to the
EGFR inhibitor lapatinib in both drug screens (our data: R = 0.96,
p = 2.363 109; CRx: R = 0.99, p = 6.23 104; Figure 7C). Pro-
teomics data also can be used to uncover mechanisms of drug
sensitivity. For example, several cell lines were hypersensitive
to the drug bleomycin, an antibiotic used to treat plantar warts
as well as many forms of cancer by inducing DNA damage.
Expression of DDX60, an antiviral RNA/DNA helicase that binds
cytosolic DNA (Miyashita et al., 2011), was most significantly
associated with sensitivity to bleomycin (R = 0.99, p = 1.1 3
1015) (Figure 7D).
We curated these drug sensitivity results to ask whether drug
sensitivity associated with (1) genetic mutations or protein
expression of the drug target itself, (2) proteins in the same
pathway as the target, or (3) other literature-supported synthetic
lethal interactions. Drug sensitivity associated strongly with both
genomic and proteomic features of known targets. For example,
we found that sensitivity to all-trans retinoic acid (ATRA) was
correlated with the expression of its target protein RXRB (R =
0.98, p = 7.91 3 109). HCC1806 cells, which expressed the
highest level of RXRB, were >200-fold more sensitive than the
median cell line (Figure 7E). The cell line DU4475, which harbors
the hyperactive BRAF-V600E mutation, was hypersensitive to
both BRAF and MEK inhibitors (6,000-fold and 100,000-fold
versus median, respectively) despite similar expression of the
target proteins.
Another potential mechanism of drug sensitivity is synthetic
lethality, in which the right combination of genetic, proteomic,
or pharmacologic perturbations leads to cell death. Synthetic
lethality tends to occur between proteins in the same pathway.
For example, the AKT1/2 inhibitor MK-2206 was not associated
with expression of AKT isoforms, but was significantly associ-
ated with expression of RPS6KB2 (R = 0.84, p = 3.54 3 104)
(Figure 7F), which lies downstream in the signaling pathway
(Shaw and Cantley, 2006). Other drugs correlated with proteins
that are not known to be in the same pathway, but have been
previously proposed to be synthetic lethal relationships in
genetic datasets. For example, poly-ADP ribose polymerase
(PARP) inhibition disrupts DNA repair leading to genotoxic stress
and cellular senescence, a process shown to be accelerated in
overactive AKT-signaling mutants (Chatterjee et al., 2013;
Mendes-Pereira et al., 2009). In our data, AKT protein expression
was also significantly correlated with sensitivity to PARP inhibi-
tion using AG-014699 (R = 0.74, p = 0.0014) (Figure 7G).
We explored how the differences in drug sensitivity and target
expression between members of a signaling pathway relate to
pathway structure. In the Akt-mTOR-S6K-signaling pathway, ri-
bosomal protein S6 kinases (RPS6KB1/2) are activated by
mTOR. Curiously, despite its association with MK-2206 sensi-
tivity, expression of either RPS6KB1 or RPS6KB2 was inversely
correlated with the S6K inhibitor PF-4708671 in luminal breast
cancer cells (R =0.96, p = 0.04) (Figure S5A). This is consistent
with the suggestion that S6K inhibition may amplify upstream
cancer signaling due to the chronic ablation of a negative feed-
back loop (Carracedo et al., 2008; Manning, 2004). Thus, the
tumorigenic action of this protein may be best targeted indirectlyCell Reports 11, 630–644, April 28, 2015 ª2015 The Authors 639
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Figure 7. Protein Expression and Drug Sensitivity
(A) Distribution of drug sensitivity (log10IC50) values across 16 TNBC cell lines for each drug in order of increasing median sensitivity. Drugs with sub-micromolar
IC50 in at least one cell line are shown. Gray dots represent outlier values (>1.53 interquartile range).
(B) Hierarchical clustering of drug-protein associations. Pairwise Pearson’s correlation was calculated systematically between drug sensitivity (inverted IC50) and
protein abundance (iBAQ) values and clustered in both dimensions. Enriched gene ontology terms are shown for several clusters with Benjamini-Hochberg
adjusted p value.
(C) Association of drug sensitivity with EGFR expression. The EGFR inhibitor lapatinib was significantly associated in both drug screen datasets (CRx: p = 6.23
104, our data: p = 2.4 3 109, FDR < 0.05).
(legend continued on next page)
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(Figure S5B). Unlike RPS6KB2, RPS6KB1 expression did not
correlate with AKT1/2 inhibitor MK-2206 sensitivity but instead
was most highly correlated with the p21-activated kinase (PAK)
inhibitor IPA-3 (R = 0.99, p = 1.91 3 1012). Based on images
from the Human Protein Atlas, RPS6KB1 and PAK2 are localized
to the nucleus whereas RPS6KB2 and PAK1 are cytoplasmic
(Uhlen et al., 2010). Thus, the reported activation of PAK1 down-
stream of S6K (Ishida et al., 2007) might be localized and isoform
specific. Together, these results demonstrate that integrated
analysis of drug sensitivity and protein expression provides a
useful strategy for selecting drugs, finding diagnostic markers,
and identifying potential mechanisms of cellular signaling.
Further experimentation will be required to confirm these
findings.
Finally, to demonstrate the potential clinical utility of these re-
sults, we asked how many proteins from the drug association
analysis could be identified in primary tumors. We found that
73% (6,798/9,292) were quantifiable in the four clinical speci-
mens we analyzed (Figure S5C). Of these, 494 were at least
5-fold more abundant than the average sample in at least one tu-
mor. For example, the abundance of the protein kinase AKT2
was higher in one of the tumor samples than in any cell line
analyzed in this study (Figure S5D).
DISCUSSION
Despite the success of large-scale ‘‘-omic’’ studies in providing
molecular targets for therapeutic intervention, these studies
have been limited by the lack of comprehensive protein data.
Mass spectrometry-based proteomics has advanced rapidly,
and it has become routine to reproducibly quantify near-com-
plete proteomes using this technology. Here we used mass
spectrometry to interrogate the proteomes of TNBC. We then in-
tegrated proteomics, genomics, and drug sensitivity data to
study the effects of genomic aberrations in the proteome and
build predictive models of drug response using proteomics.
This dataset is a useful resource to further explore the biology
of TNBC. For example, many of the recently described metasta-
tic stem cell pathways were highly expressed at the protein level
in TNBC compared to luminal breast cells. The most invasive
TNBC cells and solid tumors expressed low levels of proteins
involved in cell proliferation and high levels of proteins involved
in the epithelial-to-mesenchymal transition. Thus, the highly
specialized nature of metastatic TNBC cells may be one reason
they are so difficult to treat using conventional cytotoxic agents
that target highly proliferative cells. Precise knowledge of the
proteomes of these cells can guide the development of new
drugs to target the metastatic transition.(D) Association of protein expression with bleomycin sensitivity. The protein DD
FDR < 0.05).
(E–G) Pairwise comparisons of protein expression and drug sensitivity for three e
sensitivity to the drug; (F) pathway target, expression of a protein in the pathway
lethal, expression of a protein in an independent pathway from the drug target in
sensitivity (inverse IC50, M
1) across the same cell lines. RXRB, retinoid X recep
threonine-protein kinase; ATRA, RXR agonist all-trans retinoic acid; MK-2206, pa
Pearson’s correlation and p value are indicated below the plots. CRx data from Y
from the CRx were included. Missing IC50 values were not imputed.Machine learning has become a useful tool to capture the mo-
lecular features responsible for differences in drug sensitivity
(Barretina et al., 2012; Costello et al., 2014; Weinstein et al.,
1997; Yang et al., 2013). Statistically significant differences in
drug sensitivity based on cellular subtype have been observed
(Lehmann et al., 2011), but the effect sizes are small compared
to treatment strategies directed toward precise molecular in-
sults. Examples include ERBB2 amplification (trastuzumab),
BCR-ABL fusion (imatinib), or BRAF-V600E mutation (vemurafe-
nib), all of which result in orders-of-magnitude increases in drug
sensitivity. In reality, large-effect sizes are needed to make an
impact in the clinic. In this study, drug sensitivity and the expres-
sion of cancer-related proteins were not generally attributable to
subtypes derived by clustering global protein profiles. Consid-
ering these cells were all derived from the same tissue type
(breast) and were cultured in the same conditions, the dynamic
range and specificity of protein expression for established regu-
latory proteins and drug targets was surprising. Using regression
and prior knowledge to interrogate mechanisms of protein
expression in drug sensitivity, we found that, in many cases,
drug sensitivity was strongly correlated with the expression of
the drug target itself (e.g., retinoic acid receptors, EGFR) or pro-
teins in the same biological pathway (e.g., S6K expression as a
marker for sensitivity to AKT inhibitors).
With the exception of drugs targeting amplified genes, the
importance of protein expression in drug efficacy might be
underestimated. While it is evident that the target of a drug
must be expressed at some level in order for the drug to take ef-
fect, many drugs are developed with the assumption that the
target is expressed at similar levels in all cells. Even in the case
of gene amplification, CN does not fully account for differences
in protein expression among specimens. In any case, quantita-
tive analysis of drug targets and genetic abnormalities at the
protein level might represent a useful addition to the current
adjuvant therapy selection algorithm. Indeed, this is already
routine for estrogen, progesterone, and epidermal growth factor
receptor-2. Larger panels of cell lines will be necessary to cap-
ture rare genetic events and to enable more robust machine-
learning approaches. This will facilitate the discovery of less
obvious markers of drug sensitivity, such as synthetic lethal in-
teractions. Proteomics also could provide an indispensable
tool to rescue clinical trial results that do not improve patient out-
comes in aggregate, but have many exceptional responses that
might be due to underlying molecular features.
This study builds on other deep proteomic characterizations of
cancer (Geiger et al., 2012b; Moghaddas Gholami et al., 2013;
Nagaraj et al., 2011; Zhang et al., 2014) and represents the
first deep proteome characterization targeting TNBC. With theX60 was significantly associated with bleomycin sensitivity (p = 1.1 3 1015,
xamples are shown. (E) Direct target, expression of the target protein indicates
of the drug target, but not the target itself, indicates sensitivity; (G) synthetic
dicates sensitivity; (left) protein abundance (iBAQ) across cell lines; (right) drug
tor beta; RPS6KB2, ribosomal protein S6 kinase-2; AKT1, RAC-alpha serine/
n-isoform AKT inhibitor; AG-014699, poly-ADP ribose polymerase 1/2 inhibitor.
ang et al., (2013). (A) includes only data generated in this study. For (B–G), data
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development of large -omics approaches, personalized, predic-
tive medicine is the prevailing direction of next-generation
healthcare technology (Tian et al., 2012). Systematic, data-
driven approaches are necessary to meet this goal. We antici-
pate that genome-scale nucleic acid sequencing and protein
analysis will provide the basic molecular diagnostics toolbox
for precision cancer medicine. TNBC is one of many unmet clin-
ical needs that will benefit from future research in this area.
EXPERIMENTAL PROCEDURES
Sample Preparation
Samples were lysed in denaturing buffer and centrifuged at 12,000 3 g for
10 min to pellet insoluble material. Protein extracts were reduced with
5 mM DTT at 55C and alkylated with 15 mM iodoacetamide at room temper-
ature in the dark. Extracts from each sample (25 mg) were diluted and
digested in solution overnight with either LysC (Wako Pure Chemicals Indus-
tries) or sequencing-grade trypsin (Promega). Peptides were desalted and
fractionated on StageTips (Rappsilber et al., 2007) by basic reverse-phase
using a stepwise gradient of increasing acetonitrile (5%, 10%, 15%, 25%,
and 80%) in 0.1% NH4OH. The resulting fractions were analyzed by LC-
MS/MS.
LC-MS/MS
Peptide fractions were analyzed on an EASY-nLC-1000 (Thermo Scienti-
fic) coupled to a hybrid quadrupole-orbitrap Q-Exactive mass spectrom-
eter (Thermo Scientific) configured for data-dependent acquisition. Raw
mass spectra were searched using Sequest (release 2012.01.0 of UW Se-
quest) against a concatenated forward and reverse version of the Uniprot
human protein sequence database (v11/29/2012). Peptide spectral
matches for all fractions corresponding to the same sample were filtered
to reach a protein identification FDR of less than 1%, resulting in an
aggregate peptide-level FDR of less than 0.1% for the entire dataset. Pro-
tein quantifications were calculated using the iBAQ approach (Schwan-
ha¨usser et al., 2011).
Drug Screen and Curve Fitting
Compounds were added to cells using the CyBi-Well Vario Workstation
(CyBio) and incubated at 37C, 5% CO2 for 96 hr. Cell viability was measured
by luminescence using quantitation of ATP as an indicator of metabolically
active cells. Measurements were corrected for background luminescence
and percentage cell viability was reported as relative to the DMSO solvent con-
trol. Non-linear curve fitting was performed using MATLAB’s nlinfit function
(MathWorks). External drug sensitivity data (IC50) was downloaded from the
Genomics of Drug Sensitivity in Cancer resource (Yang et al., 2013), release
2.0 (http://www.cancerrxgene.org).
Statistical Analysis
Significance tests and correlation analysis were performed using built-in
functions of Microsoft Office Excel 2013 or R statistical computing envi-
ronment version 3.1.0. Gene enrichment significance testing was per-
formed in DAVID version 6.7 using the EASE metric, a modified Fisher’s
exact test (Huang et al., 2009). All error bars represent SD unless other-
wise noted.
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